MetaVia to Showcase DA-1726 Phase 1 Clinical Data at 2026 Precision Liver Symposium
MetaVia Inc., a clinical-stage biotechnology firm based in Cambridge, Massachusetts, has recently made headlines with the announcement that it will be sharing compelling Phase 1 clinical trial results for its drug candidate DA-1726 at the upcoming Precision Liver Symposium 2026. This symposium will be held in Denver, Colorado, on November 4, 2026. The drug, which is being developed as a dual oxyntomodulin (OXM) analog, represents a promising new option targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, crucial in managing cardiometabolic diseases.
The oral presentation is scheduled for 1:35 PM MT, featuring the expertise of Dr. Sarah Browne, the Chief Medical Officer at MetaVia. Her presentation will highlight the significant findings from the randomized placebo-controlled trial, where DA-1726 demonstrated remarkable efficacy. The study reported not only a significant reduction in MRI-PDFF (Magnetic Resonance Imaging-Proton Density Fat Fraction) but also showed effective weight loss while maintaining lean muscle mass—a critical factor in metabolic health.
DA-1726 operates through a dual agonist mechanism, stimulating GLP-1 receptors to curb hunger and enhance energy expenditure. Pre-clinical studies conducted on mice suggest that DA-1726 may yield superior weight loss results compared to existing treatments like semaglutide (Wegovy®). In addition to effective weight loss, the compound also promotes similar reductions in body weight when compared to drugs such as tirzepatide (Zepbound®) and survodutide, showing promise in preserving skeletal muscle mass.
The Phase 1 trial results are particularly exciting, as the 32 mg dosage of DA-1726 showcased best-in-class potential in reducing body weight, addressing glucose control, and decreasing waist circumference. These outcomes are crucial for those struggling with obesity and other related cardiometabolic issues, which affect millions globally.
Beyond DA-1726, MetaVia is also working on another innovative treatment, vanoglipel (DA-1241), aimed at combating Metabolic Dysfunction-Associated Steatohepatitis (MASH). This candidate is anticipated to be a first-in-class option leveraging G-protein-coupled receptor 119 (GPR119) pathways, and preclinical studies have suggested it could significantly improve metabolic markers, offering an added layer of potential effectiveness against liver diseases.
The upcoming Precision Liver Symposium is an excellent platform for MetaVia to engage with the scientific community, share advancements in the field of cardiometabolic treatments, and showcase their commitment to addressing pressing health concerns related to liver and metabolic diseases.
For more updates about MetaVia, please visit MetaVia's official website.
It is important to note that certain aspects of the press release include forward-looking statements that may involve risks and uncertainties. Investors and stakeholders should consider these predictions with caution while acknowledging the dynamic nature of pharmaceutical development and regulatory processes.
The oral presentation is scheduled for 1:35 PM MT, featuring the expertise of Dr. Sarah Browne, the Chief Medical Officer at MetaVia. Her presentation will highlight the significant findings from the randomized placebo-controlled trial, where DA-1726 demonstrated remarkable efficacy. The study reported not only a significant reduction in MRI-PDFF (Magnetic Resonance Imaging-Proton Density Fat Fraction) but also showed effective weight loss while maintaining lean muscle mass—a critical factor in metabolic health.
DA-1726 operates through a dual agonist mechanism, stimulating GLP-1 receptors to curb hunger and enhance energy expenditure. Pre-clinical studies conducted on mice suggest that DA-1726 may yield superior weight loss results compared to existing treatments like semaglutide (Wegovy®). In addition to effective weight loss, the compound also promotes similar reductions in body weight when compared to drugs such as tirzepatide (Zepbound®) and survodutide, showing promise in preserving skeletal muscle mass.
The Phase 1 trial results are particularly exciting, as the 32 mg dosage of DA-1726 showcased best-in-class potential in reducing body weight, addressing glucose control, and decreasing waist circumference. These outcomes are crucial for those struggling with obesity and other related cardiometabolic issues, which affect millions globally.
Beyond DA-1726, MetaVia is also working on another innovative treatment, vanoglipel (DA-1241), aimed at combating Metabolic Dysfunction-Associated Steatohepatitis (MASH). This candidate is anticipated to be a first-in-class option leveraging G-protein-coupled receptor 119 (GPR119) pathways, and preclinical studies have suggested it could significantly improve metabolic markers, offering an added layer of potential effectiveness against liver diseases.
The upcoming Precision Liver Symposium is an excellent platform for MetaVia to engage with the scientific community, share advancements in the field of cardiometabolic treatments, and showcase their commitment to addressing pressing health concerns related to liver and metabolic diseases.
For more updates about MetaVia, please visit MetaVia's official website.
It is important to note that certain aspects of the press release include forward-looking statements that may involve risks and uncertainties. Investors and stakeholders should consider these predictions with caution while acknowledging the dynamic nature of pharmaceutical development and regulatory processes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.